# Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct07757464` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07757464](<https://clinicaltrials.gov/study/NCT07757464>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07757464

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 125 participants.

## Technical summary

Registry record NCT07757464. Randomized; single masking; primary purpose treatment. Start 2026-08-10 (actual); primary completion 2027-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 125 participants (planned count; ClinicalTrials.gov record NCT07757464, source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)
- Started: 2026-08-10 (actual) (ClinicalTrials.gov record NCT07757464, source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)
- Primary completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07757464, source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)
- Completion: 2027-01-30 (anticipated) (ClinicalTrials.gov record NCT07757464, source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07757464, source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07757464-2026-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes
- Acronym: PREVENT-SIH
- Condition: Diabetes Mellitus, Type 2
- Condition: Hyperglycemia Due to Type 2 Diabetes Mellitus
- Condition: Osteoarthritis, Knee
- Intervention (Drug): Insulin Isophane Human, NPH, Pre-emptive Algorithm
- Intervention (Drug): Triamcinolone Acetonide Knee Injection
- Lead sponsor: Shifa International Hospital
- Lead sponsor class: OTHER
- Collaborator: Al Ain University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 2283d8090c4c3953be43a486ed5c6fd345ed3cafe7013c166a7532caed6b0553
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
